当前位置:中国食品安全法治网 >> Overseas >> 浏览文章
Views wanted on a novel food supplement
来源:Food Standards Agency 作者:佚名 日期:2013年03月20日

A Japanese company has applied to the Food Standards Agency for approval to market a strain of the bacterium Clostridium butyricum as a novel food ingredient for use in food supplements. Views are wanted on the draft opinion prepared by the FSA's independent committee of experts.

The company, Miyarisan Pharmaceutical Co., plans to market Clostridium butyricum (strain CBM 588) as a probiotic food supplement. The bacterium would be produced as spores in tablet form. Any claims relating to probiotic function were not assessed during this safety evaluation, and will need to be assessed separately under the EU Nutrition and Health Claims Regulation.

Some species of clostridium are found in human and animal gut as part of the normal microflora.

The applicant has marketed preparations of this strain for use as a probiotic in Japan and other Asian countries for several decades and is now intending to market these supplements in the European Union (EU). The strain has also received EU approval as a microbial feed additive for chickens and piglets.

 

About novel food

A novel food is a food or food ingredient that does not have a significant history of consumption within the European Union before 15 May 1997.

Before any new food product can be introduced on the European market, it must be assessed rigorously for safety. In the UK, the assessment of novel food is carried out by the Advisory Committee on Novel Foods and Processes (ACNFP).

 

返回首页】【发表评论】【告诉好友】【打印此文】【收藏此文】【关闭窗口
上一篇:Food security law will not meet nutritional norms: RTF campaign
下一篇:HPA publishes Cryptosporidium investigation findings
发表评论

 
加入收藏 | 设为首页 | | 关于我们 | 免责声明 | 联系我们 |
网络110
报警服务
中 国
互联网协会
京ICP备
09038275号
不良信息
举报中心
北京网络
行业协会
中国文明网
传播文明
友荐云推荐